NCT06382168View on ClinicalTrials.gov

DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 12, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

June 30, 2026

Conditions
Leukemia, Myeloid, Acute
Interventions
DRUG

DFP-10917

DFP-10917 4 mg/m\^2/day is given as a continuous 14-day intravenous infusion, followed by a 14-day rest in each 28-day cycle.

DRUG

Venetoclax

Venetoclax 400 mg once daily for 10-14 days, followed by a 14-day rest in each 28-day cycle.

Trial Locations (4)

22911

RECRUITING

University of Virginia Cancer Center, Charlottesville

27157

RECRUITING

Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

92868

RECRUITING

UCI Chao Family Comprehensive Cancer Center, Orange

05401

RECRUITING

University of Vermont Cancer Center, Burlington

Sponsors
All Listed Sponsors
lead

Delta-Fly Pharma, Inc.

INDUSTRY